Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,829,762
  • Shares Outstanding, K 577,238
  • Annual Sales, $ 2,264 M
  • Annual Income, $ 858,980 K
  • EBIT $ 1,533 M
  • EBITDA $ 1,552 M
  • 60-Month Beta 0.43
  • Price/Sales 9.63
  • Price/Cash Flow 9.47
  • Price/Book 2.39

Options Overview Details

View History
  • Implied Volatility 29.80% (-11.14%)
  • Historical Volatility 19.22%
  • IV Percentile 27%
  • IV Rank 19.06%
  • IV High 75.80% on 01/14/26
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 33) 2.42 (6.13%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 209
  • Volume Avg (30-Day) 592
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 10,096
  • Open Int (30-Day) 10,633
  • Expected Range 37.13 to 41.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.33
  • Number of Estimates 4
  • High Estimate 1.41
  • Low Estimate 1.13
  • Prior Year 1.15
  • Growth Rate Est. (year over year) +15.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.20 +3.53%
on 12/19/25
41.70 -5.16%
on 01/08/26
+1.17 (+3.05%)
since 12/16/25
3-Month
35.92 +10.12%
on 10/28/25
41.70 -5.16%
on 01/08/26
+3.21 (+8.83%)
since 10/16/25
52-Week
29.66 +33.34%
on 04/07/25
41.70 -5.16%
on 01/08/26
+8.60 (+27.79%)
since 01/16/25

Most Recent Stories

More News
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple...

RPRX : 39.55 (-0.43%)
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...

RPRX : 39.55 (-0.43%)
TEVA : 31.76 (-1.82%)
Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary...

RPRX : 39.55 (-0.43%)
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

RPRX : 39.55 (-0.43%)
3 Overrated Stocks We Steer Clear Of

3 Overrated Stocks We Steer Clear Of

RPRX : 39.55 (-0.43%)
LASR : 43.94 (+0.25%)
CRL : 219.70 (-1.69%)
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for...

RPRX : 39.55 (-0.43%)
3 Healthcare Stocks We’re Skeptical Of

3 Healthcare Stocks We’re Skeptical Of

RPRX : 39.55 (-0.43%)
PGNY : 24.52 (+0.86%)
ANIP : 84.83 (-0.54%)
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an...

RPRX : 39.55 (-0.43%)
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty...

RPRX : 39.55 (-0.43%)
DNLI : 17.99 (-4.21%)
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty...

RPRX : 39.55 (-0.43%)
DNLI : 17.99 (-4.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 40.20
2nd Resistance Point 39.99
1st Resistance Point 39.77
Last Price 39.55
1st Support Level 39.34
2nd Support Level 39.13
3rd Support Level 38.91

See More

52-Week High 41.70
Last Price 39.55
Fibonacci 61.8% 37.10
Fibonacci 50% 35.68
Fibonacci 38.2% 34.26
52-Week Low 29.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar